Article Text

Download PDFPDF
Biology and bias: do we have the will to improve cardiovascular disease outcomes for women?
  1. Janet Wei1,
  2. Timothy D Henry2,
  3. C Noel Bairey Merz1
  1. 1 Barbara Streisand Women’s Heart Center, Cedars-Sinai Smdit Heart Institute, Los Angeles, California, USA
  2. 2 Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
  1. Correspondence to Dr C Noel Bairey Merz, Barbara Streisand Women’s Heart Center, Smidt Cedars-Sinai Heart Institute, Los Angeles CA 90048, USA; Noel.BaireyMerz{at}cshs.org

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sex differences in acute myocardial infarction (AMI): biology and bias

Women with AMI have higher mortality than men with AMI, but multiple factors contribute to this sex difference, including biological variables related to sex such as older age at presentation and increased cardiovascular risk profile, as well as gender bias including disparities in reperfusion time and AMI treatment in women. Notably, the largest sex discrepancy in AMI survival is among young women <65 years when compared with similarly aged men1; younger women are the only group with rising cardiovascular disease (CVD) death rates compared with declines in all others.2 3 Understanding both biological sex differences and gender bias in AMI treatment is essential to improve CVD outcomes for all.

New findings

A new report4 using the recently developed and validated European Society of Cardiology Acute Cardiovascular Care Association (ACCA) Quality Indicators (QIs) for AMI offers insight into improving outcomes for women. These investigators found that women in England and Wales less frequently received guideline-indicated AMI care and had significantly higher mortality than men. Specifically, among 691 290 patients in the UK Myocardial Ischaemia National Audit Project, women less likely received timely reperfusion therapy for ST-Elevation Myocardial Infarction (STEMI), coronary angiography for Non-ST-elevation Myocardial Infarction (NSTEMI), dual antiplatelet therapy and secondary prevention therapies. Notably, this suboptimal care existed despite a more adverse biological 30-day Global Registry of Acute Coronary Events (GRACE) risk score adjusted mortality in women compared with men. The authors estimated that 8243 deaths in women were potentially preventable had care been equal between sexes.

Why is AMI care unequal? Biology drives bias

Biological sex differences in AMI likely drive differences in administration of and response to guidelines-based therapy. For example, compared with men, women are less likely to have a culprit lesion identified at the time of angiography and more likely to …

View Full Text

Footnotes

  • Contributors All authors contributed equally to the drafting, editing and approval of the final manuscript.

  • Funding This work was supported by contracts from the National Heart, Lung and Blood Institutes, nos. N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164, grants U01 64829, U01 HL649141, U01 HL649241, T32 HL69751 and 1R03 AG032631 from the National Institute on Aging, K12 HD051959 Building Interdisciplinary Research Careers in Women’s Health (Taqueti), GCRC grant MO1-RR00425 from the National Center for Research Resources and grants from the Gustavus and Louis Pfeiffer Research Foundation, Danville, New Jersey, The Women’s Guild of Cedars-Sinai Medical Center, Los Angeles, California, The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, Pennsylvania, and QMED, Inc, Laurence Harbor, New Jersey, the Edythe L. Broad Women’s Heart Research Fellowship, Cedars-Sinai Medical Center, Los Angeles, California, and the Barbra Streisand Women’s Cardiovascular Research and Education Program, Cedars-Sinai Medical Center, Los Angeles.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles